PROMOTE IR800 IAB2M (Stage 2)
Trial Status: Open to Recruitment
This is a single-centre study in those with high-risk prostate cancer.
Aims and Objectives
This study aims to test new imaging techniques in high-risk prostate cancer patients who are likely to have spreading disease that cannot be seen with the naked eye. Patients are injected with a special dye which carries a specific marker (IR800 IAB2M) that marks prostate cells only, and a special camera is used to make them shine in the dark. During keyhole surgery, the special dye and camera should allow the surgeon to see cancer cells, and the ‘shining’ areas will be sampled to check that they are cancerous. The aim of this study is to test whether the combination of the new dye and camera helps to see whether cancer has spread, and improves the precision of surgical removal of cancer, at the same time as avoiding unnecessarily removing healthy tissue.
PROMOTE is a randomised, interventional trial. Design type: treatment, drug, imaging, surgery.
Please visit the ISRCTN webpage for this trial for further information.